ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Mirvaso 3 mg/g gel

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.

**Excipient(s) with known effect:**
One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Gel.

White to light yellow opaque aqueous gel.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.

4.2 Posology and method of administration

**Posology**

One application per 24 hours, at any time suitable for the patient, for as long as facial erythema is present.

The maximum daily recommended dose is 1 g of gel in total weight, which corresponds to approximately five pea sized amounts.

Treatment should be initiated with a smaller amount of gel (less than the maximum) for at least one week. The amount of gel can then be increased gradually based on tolerability and patient response.

**Special populations**

*Elderly patients*

The experience of use of Mirvaso in patients aged above 65 years is limited (see also section 4.8).

*Paediatric population*

The safety and efficacy of Mirvaso in children and adolescents aged less than 18 years have not been established. No data are available.

Mirvaso is contraindicated in children aged less than 2 years because of serious systemic safety risk (see section 4.3). Safety concerns related to the systemic absorption of brimonidine have also been identified for the age group 2 to 12 years (see section 4.9). Mirvaso should not be used in children or adolescents aged 2 to 18 years.
Method of administration

Cutaneous use only.

Mirvaso should be applied smoothly and evenly as a thin layer across the entire face (forehead, chin, nose and both cheeks) avoiding the eyes, eyelids, lips, mouth and membrane of the inner nose. Mirvaso should be applied only to the face.

Hands should be washed immediately after applying the medicinal product.

Mirvaso can be used in conjunction with other cutaneous medicinal products for the treatment of inflammatory lesions of rosacea and with cosmetics. These products should not be applied immediately before the daily application of Mirvaso; they may be used only after the applied Mirvaso has dried.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children aged less than 2 years.

Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or moclobemide) and patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline, mianserin or mirtazapin) antidepressants which affect noradrenergic transmission.

4.4 Special warnings and precautions for use

Mirvaso should not be applied on irritated skin (including following laser therapy) or open wounds. In case of severe irritation or contact allergy, the treatment with the medicinal product should be discontinued.

Exacerbation of rosacea symptoms is very common in patients treated with Mirvaso. Across all clinical studies, 16% of patients receiving Mirvaso experienced an event of symptom exacerbation. Treatment should be initiated with a small amount of gel and the dose increased gradually, based on tolerability and response to treatment (see section 4.2).

Erythema and Flushing

The effect of Mirvaso topical gel begins to diminish hours after application. In some patients, erythema and flushing were reported to return with greater severity than was present at baseline. Most of the cases were observed within the first 2 weeks of starting the treatment (see section 4.8).

The onset of flushing relative to application of Mirvaso topical gel varied, ranging from approximately 30 minutes to several hours (see section 4.8).

In the majority of these cases, erythema and flushing resolved after discontinuation of Mirvaso topical gel.

In case worsening of erythema occurs, Mirvaso topical gel should be discontinued. Symptomatic measures, such as cooling, NSAID and antihistamines, may help in alleviating symptoms.

Recurrences of aggravated erythema and flushing have been reported after re-administration of Mirvaso topical gel. Prior to resuming treatment after temporary discontinuation due to aggravated erythema or flushing, perform a test application on a small area of the face for at least one day before full facial application is resumed.

It is important to inform the patient not to exceed the recommended maximum dose (5 pea size amounts) and frequency of application (once daily).
Mirvaso should not be applied close to the eyes.

Mirvaso has not been studied in patients with renal or hepatic impairment.

Any increase in the daily amount applied above 5 pea sized amounts and/or increase in frequency of daily application of the medicinal product should be avoided, since the safety of higher daily doses or repeated daily application has not been assessed.

The concomitant use of other systemic alpha adrenergic receptor agonists may potentiate the undesirable effects of this class of medicinal products in patients:
- with severe or unstable or uncontrolled cardiovascular disease;
- with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren’s syndrome.

The medicinal product contains methylparahydroxybenzoate (E218) which may cause allergic reactions (possibly delayed), and propylene glycol which may cause skin irritation.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Mirvaso is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and patients on tricyclic or tetracyclic antidepressants which affect noradrenergic transmission (see section 4.3).

The possibility of an additive or potentiating effect with central nervous system depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered.

No data on the level of circulating catecholamines after Mirvaso administration are available. Caution, however, is advised in patients taking substances which can affect the metabolism and uptake of circulating amines e.g. chlorpromazine, methylphenidate, reserpine.

Caution is advised when initiating (or changing the dose of) a concomitant systemic substance (irrespective of pharmaceutical form) which may interact with alpha adrenergic receptor agonists or interfere with their activity i.e. agonists or antagonists of the adrenergic receptor e.g. (isoprenaline, prazosin).

Brimonidine may cause clinically insignificant decreases in blood pressure in some patients. Caution is therefore advised when using medicinal products such as anti-hypertensives and/or cardiac glycosides concomitantly with brimonidine.

4.6 Fertility, pregnancy and lactation

Pregnancy
There are no or limited amount of data from the use of brimonidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Mirvaso during pregnancy.

Breast-feeding
It is unknown whether brimonidine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Mirvaso should not be used during breast-feeding.

Fertility
Brimonidine did not present any special reproductive or developmental hazard in animal species.
4.7 Effects on ability to drive and use machines

Mirvaso has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most commonly reported adverse reactions are erythema, pruritus, flushing and skin burning sensation, all occurring in 1.2 to 3.3% of patients in clinical studies. They are typically mild to moderate in severity, and usually do not require discontinuation of treatment. No meaningful differences in the safety profiles were observed between the elderly subject population and subjects 18 to 65 years of age. Aggravated erythema, flushing and skin burning sensation have been reported during the post-marketing period (see section 4.4).

Tabulated list of adverse reactions

The adverse reactions are classified by System Organ Class and frequency, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data) and were reported with Mirvaso in clinical studies (see Table 1).

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>Adverse reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac disorders</td>
<td>Rare</td>
<td>Bradycardia*</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Uncommon</td>
<td>Headache, paraesthesia</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Uncommon</td>
<td>Eyelid oedema</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Common</td>
<td>Flushing, pallor at the application site*</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Dizziness*</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Hypotension*</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Uncommon</td>
<td>Nasal congestion</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Uncommon</td>
<td>Dry mouth</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Common</td>
<td>Erythema, pruritus, skin burning sensation</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Acne, allergic contact dermatitis, contact dermatitis, dermatitis, dry skin, pain of skin, skin discomfort, rash papular, rosacea, skin irritation, skin warm, swelling face*, urticaria*</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Angioedema*</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Uncommon</td>
<td>Feeling hot, peripheral coldness</td>
</tr>
</tbody>
</table>

* Adverse reactions reported from post-marketing data.

Description of selected adverse reactions

Bradycardia and hypotension

Post-marketing cases of bradycardia, hypotension (including orthostatic hypotension) and dizziness have been reported, some of which required hospitalization. Some cases involved application of Mirvaso following laser procedures (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
4.9 Overdose

Overdoses after oral use of other alpha2-agonists have been reported to cause symptoms such as hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmias, miosis, apnoea, hypotonia, hypothermia, respiratory depression and seizure.

Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.

No cases of overdose after cutaneous use of Mirvaso were reported during the clinical development program.

Paediatric population

Serious adverse reactions following inadvertent ingestion of Mirvaso by two young children of one clinical study subject have been reported. The children experienced symptoms consistent with previously reported oral overdoses of alpha2-agonist in young children. Both children were reported to have made a full recovery within 24 hours.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other dermatological preparations, Other dermatologicals, ATC code: D11AX21.

Mechanism of action

Brimonidine is a highly selective alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenergic receptor than the alpha1-adrenergic receptor.

Pharmacodynamic effects

Cutaneous facial application of a highly selective alpha2-adrenergic receptor agonist reduces erythema through direct cutaneous vasoconstriction.

Clinical efficacy and safety

The efficacy of Mirvaso in the treatment of moderate to severe facial erythema of rosacea has been demonstrated in two randomised, vehicle controlled blinded clinical trials, which were identical in design. Moderate to severe erythema was defined as a grade 3 or greater on both the Clinician Erythema Assessment (CEA) scale and Patient Self-Assessment (PSA) scale. The studies were conducted in 553 randomised subjects aged 18 years and older who were treated once daily for 4 weeks with either Mirvaso or vehicle. Of these, 539 completed 29 days of treatment and had data available to be included in the efficacy analysis at Day 29, with the majority being Caucasians between 18 and 65 years of age.

The primary endpoint was expressed in terms of composite success i.e. subjects responding with a 2-grade reduction on both baseline CEA score and baseline PSA score on Day 29. The results from both clinical studies demonstrated that Mirvaso was significantly more effective (p<0.001) in the reduction of facial erythema of rosacea than vehicle gel when applied once daily for 29 days (primary endpoint, see Table 2). For the population subset of patients with severe erythema at baseline Day 1 (i.e. subjects with CEA or PSA grade of 4) which represented 26% of the randomised subjects, the results on the primary endpoint on Day 29 were similar to those results observed in the overall population (see Table 3) and were statistically significant for both studies combined (p=0.003). In addition, for the overall population, Mirvaso demonstrated statistical superiority (p<0.001) over vehicle gel with respect to rapid initial onset of a clinically meaningful effect (1-Grade Composite Success for CEA and PSA) after the first application at 30 minutes on Day 1 (secondary endpoint 27.9% vs. 6.9% for Study 1, 28.4% vs. 4.8% for Study 2), and to achievement of a clinically
meaningful effect (1-Grade Composite Success for CEA and PSA) on Day 29 (tertiary endpoint, see Table 4).

CEA and PSA were defined as follows:

CEA: Clinician Erythema Assessment: 0=Clear skin with no signs of erythema, 1=Almost clear; slight redness, 2=Mild erythema; definite redness, 3=Moderate erythema+ marked redness and 4=Severe erythema+ fiery redness

PSA: Patient Self-Assessment: 0=No redness, 1=Very mild redness, 2=Mild redness, 3=Moderate redness and 4=Severe redness

**Table 2: Percentage of subjects with a 2-grade improvement in both CEA and PSA**

<table>
<thead>
<tr>
<th></th>
<th>Study 1 (Mirvaso Gel n=127)</th>
<th>Study 1 (Vehicle Gel n=128)</th>
<th>Study 2 (Mirvaso Gel n=142)</th>
<th>Study 2 (Vehicle Gel n=142)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Success day 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 hours after application</td>
<td>31.5%</td>
<td>10.9%</td>
<td>25.4%</td>
<td>9.2%</td>
</tr>
<tr>
<td>6 hours after application</td>
<td>30.7%</td>
<td>9.4%</td>
<td>25.4%</td>
<td>9.2%</td>
</tr>
<tr>
<td>9 hours after application</td>
<td>26.0%</td>
<td>10.2%</td>
<td>17.6%</td>
<td>10.6%</td>
</tr>
<tr>
<td>12 hours after application</td>
<td>22.8%</td>
<td>8.6%</td>
<td>21.1%</td>
<td>9.9%</td>
</tr>
<tr>
<td>Day 29 p-value</td>
<td>&lt;0.001</td>
<td>-</td>
<td>&lt;0.001</td>
<td>-</td>
</tr>
</tbody>
</table>

**Table 3: Percentage of subjects with severe erythema at baseline Day 1 (CEA or PSA grade 4) with 2-grade improvement in both CEA and PSA**

<table>
<thead>
<tr>
<th></th>
<th>Study 1 (Mirvaso Gel n=79)</th>
<th>Study 1 (Vehicle Gel n=63)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Success day 29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 hours after application</td>
<td>22.8%</td>
<td>9.5%</td>
</tr>
<tr>
<td>6 hours after application</td>
<td>26.6%</td>
<td>7.9%</td>
</tr>
<tr>
<td>9 hours after application</td>
<td>20.3%</td>
<td>11.1%</td>
</tr>
<tr>
<td>12 hours after application</td>
<td>21.5%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Day 29 p-value</td>
<td>0.003</td>
<td>-</td>
</tr>
</tbody>
</table>

**Table 4: Percentage of subjects with a 1-grade improvement in both CEA and PSA**

<table>
<thead>
<tr>
<th></th>
<th>Study 1 (Mirvaso Gel n=127)</th>
<th>Study 1 (Vehicle Gel n=128)</th>
<th>Study 2 (Mirvaso Gel n=142)</th>
<th>Study 2 (Vehicle Gel n=142)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Success Day 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 hours after application</td>
<td>70.9%</td>
<td>32.8%</td>
<td>71.1%</td>
<td>40.1%</td>
</tr>
<tr>
<td>6 hours after application</td>
<td>69.3%</td>
<td>32.0%</td>
<td>64.8%</td>
<td>43.0%</td>
</tr>
<tr>
<td>9 hours after application</td>
<td>63.8%</td>
<td>29.7%</td>
<td>66.9%</td>
<td>39.4%</td>
</tr>
<tr>
<td>12 hours after application</td>
<td>56.7%</td>
<td>30.5%</td>
<td>53.5%</td>
<td>40.1%</td>
</tr>
<tr>
<td>Day 29 p-value</td>
<td>&lt;0.001</td>
<td>-</td>
<td>&lt;0.001</td>
<td>-</td>
</tr>
</tbody>
</table>

No clinically meaningful trends with respect to tachyphylaxis or rebound effects (worsening of baseline erythema after cessation of treatment) were observed with use of Mirvaso for 29 days.

The results from a long term open label study in 449 patients, with continuous treatment for up to one year, confirmed that chronic use of Mirvaso is safe and effective. Daily reductions in erythema for the first month of use (as measured with the CEA and PSA scales) were similar to those observed in the controlled trials, and those reductions were achievable for up to 12 months with no apparent loss of effect over time. The overall frequencies of adverse reactions in this study are reflected in Table 1 above, with the highest rates occurring in the first 29 days of use. No adverse reactions had an increase in frequency over time, and there was no evidence that long-term use of Mirvaso conveyed an increased risk of occurrence of any specific type of adverse reaction.
Concomitant use of Mirvaso with other medicinal products for the treatment of inflammatory lesions of rosacea has not been systematically investigated. However, in the long term open label study, the efficacy and safety of Mirvaso, as described above, was not affected by the concomitant use of cosmetics or other medicinal products (e.g. topical metronidazole, topical azelaic acid, and oral tetracyclines including low dose doxycycline) for the treatment of inflammatory lesions of rosacea in the concerned subpopulation (131/449 patients in the study used concomitant rosacea medicinal product).

Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with Mirvaso in all subsets of the paediatric population in treatment of rosacea (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption
The absorption of brimonidine from Mirvaso was evaluated in a clinical study in 24 adult subjects with facial erythema of rosacea. All enrolled subjects received a single-day ocular administration of a 0.2% eye drops solution of brimonidine followed by a once daily cutaneous application of Mirvaso for 29 days (intra-individual comparison of systemic exposure). On Day 1 of the study, all subjects received 1 drop of the 0.2% eye drops solution in each eye, every 8 hours over a 24-hour period (3 doses in total).

After repeated cutaneous application of Mirvaso on facial skin, no drug accumulation in plasma was observed throughout the treatment duration: the highest mean (± standard deviation) plasma maximum concentration ($C_{max}$) and area under the concentration-time curve from 0 to 24 hours (AUC$_{0-24hr}$) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL respectively. These levels are significantly lower (2-fold) than those observed following single-day ocular administration of a 0.2% eye drops solution of brimonidine.

Distribution
The protein binding of brimonidine has not been studied.

Biotransformation
Brimonidine is extensively metabolised by the liver.

Elimination
Urinary excretion is the major route of elimination of brimonidine and its metabolites.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Carbomer
Methylparahydroxybenzoate (E218)
Phenoxyethanol
Glycerol
Titanium dioxide
Propylene glycol
Sodium hydroxide
Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage condition.
Do not freeze.

6.5 Nature and contents of container

[Tube]
[2g]
Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) closure.

[10 g; 30g]
Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.

Or

[2g]
Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes with a high density polyethylene (HDPE) head and polyethylene (PE) child resistant closure

[10 g; 30g]
Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.

[Pump – 30 g]
Multidose container with airless pump system with child resistant closure.
Polypropylene (PP) / Thermoplastic Polyolefin (TPO) / high density polyethylene (HDPE) and polypropylene (PP) child resistant closure.

Pack sizes: 1 tube of 2 g, 10 g or 30 g; 1 pump of 30 g.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Galderma International
Tour Europlaza, 20 avenue André Prothin – La Défense 4
La Défense Cedex 92927
France
8. MARKETING AUTHORISATION NUMBER(S)

Polyethylene (PE)/Aluminium (Al)/Polyethylene (PE) laminated plastic tubes:
EU/1/13/904/001
EU/1/13/904/002
EU/1/13/904/003

Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes:
EU/1/13/904/004
EU/1/13/904/005
EU/1/13/904/006

Polypropylene (PP) / Thermoplastic Polyolefin (TPO) / high density polyethylene (HDPE) and polypropylene (PP) child resistant closure.
EU/1/13/904/007

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 February 2014

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Laboratoires Galderma
Z.I. Montdésir
74540 Alby-sur-Chéran
France

And

Galderma Laboratorium GmbH
Georg-Glock-Str. 8
D-40474 Düsseldorf
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription for renewable delivery.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The requirements for submission of periodic safety reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequently updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CARTON

1. NAME OF THE MEDICINAL PRODUCT
Mirvaso 3 mg/g gel
brimonidine

2. STATEMENT OF ACTIVE SUBSTANCE(S)
One gram of gel contains 3.3 mg of brimonidine.

3. LIST OF EXCIPIENTS
Excipients: Carbomer, methylparahydroxybenzoate (E218), phenoxyethanol, glycerol, titanium dioxide, propylene glycol, sodium hydroxide, purified water. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS
Gel
2g
10 g
30 g

5. METHOD AND ROUTE(S) OF ADMINISTRATION
Do not swallow.
Read the package leaflet before use.
Cutaneous use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE
EXP
9. **SPECIAL STORAGE CONDITIONS**

Do not freeze.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Galderma International  
Tour Europlaza, 20 avenue André Prothin  
La Défense 4  
92927 La Défense Cedex  
France

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/13/904/001  
EU/1/13/904/002  
EU/1/13/904/003  
EU/1/13/904/004  
EU/1/13/904/005  
EU/1/13/904/006  
EU/1/13/904/007

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Mirvaso

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC: {number} [product code]
SN: {number} [serial number]
NN: {number} [national reimbursement number or other national number identifying the medicinal product]
## PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

30 G TUBE / MULTIDOSE CONTAINER WITH AIRLESS PUMP

### 1. NAME OF THE MEDICINAL PRODUCT

Mirvaso 3 mg/g gel
brimonidine

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

One gram of gel contains 3.3 mg of brimonidine.

### 3. LIST OF EXCIPIENTS

Excipients: Carbomer, methylparahydroxybenzoate (E218), phenoxyethanol, glycerol, titanium dioxide, propylene glycol, sodium hydroxide, purified water. See leaflet for further information.

### 4. PHARMACEUTICAL FORM AND CONTENTS

Gel
30 g

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Do not swallow.
Read the package leaflet before use.
Cutaneous use only.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS

Do not freeze
| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
|     | EU/1/13/904/003 |
|     | EU/1/13/904/006 |
|     | EU/1/13/904/007 |
| 13. | BATCH NUMBER |
|     | Lot |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
| 15. | INSTRUCTIONS ON USE |
| 16. | INFORMATION IN BRAILLE |
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

10 G TUBE

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Mirvaso 3 mg/g gel
brimonidine
Cutaneous use.

2. METHOD OF ADMINISTRATION

Do not swallow.
Read the package leaflet before use.

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

10 g

6. OTHER

Keep out of the sight and reach of children.

Excipients: Carbomer, methylparahydroxybenzoate (E218), phenoxyethanol, glycerol, titanium dioxide, propylene glycol, sodium hydroxide, purified water.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

2 G TUBE

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mirvaso 3 mg/g gel</td>
</tr>
<tr>
<td>brimonidine</td>
</tr>
<tr>
<td>Cutaneous use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. METHOD OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not swallow.</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 g</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. OTHER</th>
</tr>
</thead>
</table>
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Mirvaso is and what it is used for
2. What you need to know before you use Mirvaso
3. How to use Mirvaso
4. Possible side effects
5. How to store Mirvaso
6. Contents of the pack and other information

1. What Mirvaso is and what it is used for

Mirvaso contains the active substance brimonidine which belongs to a group of medicines commonly referred to as “alpha agonists”.

It is applied to the skin of the face to treat redness due to rosacea in adult patients.

Redness of the face due to rosacea is caused by high levels of blood flow in the facial skin, which is the result of enlargement (dilation) of the small blood vessels of the skin.

When applied, Mirvaso acts to narrow these blood vessels again which reduces the excess blood flow and redness.

2. What you need to know before you use Mirvaso

Do not use Mirvaso:
- if you are allergic to brimonidine or any of the other ingredients of this medicine (listed in section 6).
- in children below 2 years of age, who may be at greater risk of side effects from any of the medicine absorbed through the skin.
- if you are taking certain medicines used for depression or Parkinson’s disease including so-called monoamine oxidase (MAO) inhibitors (for example selegiline or moclobemide) or tricyclic antidepressants (such as imipramine) or tetracyclic antidepressants (such as maprotiline, mianserin or mirtazapin).
- Use of Mirvaso when taking these medicines may result in a fall in blood pressure.

Warnings and precautions

Talk to your doctor, before using Mirvaso if:
- the skin of your face is irritated or has open wounds.
- you have problems with your heart or circulation.
- you have depression, decreased blood flow to the brain or the heart, fall in blood pressure on standing up, decreased blood flow to the hands, feet or skin, or Sjögren’s syndrome (a chronic disease in which the body’s natural defence - the immune system - attacks the moisture-producing glands).
- you have kidney or liver problems or have had them in the past.
- you have had, or plan to have any laser procedure on your skin.

It is important to start treatment with a small amount of gel, increase the dose gradually and not exceed the maximum dose (see ‘How to use Mirvaso’).

Do not apply Mirvaso more than once a day and do not exceed the maximum daily dose of 1g (approximately 5 pea sized amounts). See also instructions ‘How to use Mirvaso’.

Worsening of skin redness, flushing or burning feeling of the skin:
Up to 1 in 6 patients experience the return of their redness worse than it was initially. Such worsening of redness usually develops within the first 2 weeks of treatment with Mirvaso. Generally, it resolves spontaneously after treatment is stopped. The effect should gradually disappear within a few days in most cases. Before you restart the treatment with Mirvaso, test it on a small area of the face on a day when you can stay at home. If you do not experience worsening of redness or burning, continue with the usual treatment (see section 3).
In case of worsening or unexpected redness, discontinue the treatment and contact your doctor.

If any of the above applies to you, talk to your doctor since this medicine may not be suitable for you.

Children and adolescents
Do not give this medicine to children and adolescents under the age of 18 years because the safety and efficacy has not been established for this age group. This is particularly important in children under the age of 2 years (see ‘Do not use Mirvaso’).

Other medicines and Mirvaso
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, because these medicines could affect your treatment with Mirvaso or Mirvaso could affect your treatment with these medicines.

Do not take Mirvaso with selegiline, moclobemide, imipramine, mianserin, or maprotiline, which are medicines that can be used for depression or Parkinson’s disease, as this could lead to a change in the effectiveness of Mirvaso or could increase the chances for side effects such as a fall in blood pressure (see under ‘Do not use Mirvaso’).

Also, tell your doctor if you are taking any of the following medicines:
- medicines used for the treatment of pain, sleep disorders, or anxiety disorders
- medicines used for the treatment of psychiatric disorders (chlorpromazine) or used for hyperactivity (methylphenidate) or used for high blood pressure (reserpine).
- medicines which act on the same body mechanism as Mirvaso (other alpha agonists, e.g. clonidine; so-called alpha blockers or alpha antagonists, e.g. prazosin, isoprenaline which are most often used for treatment of high blood pressure, slow heart rate or asthma).
- cardiac glycosides (e.g. digoxin), used to treat heart problems.
- blood pressure lowering medicine such as beta-blockers or calcium channel blockers (e.g. propranolol, amlodipine).

If any of the above applies to you, or if you are unsure, talk to your doctor.

Mirvaso with alcohol
Tell your doctor if you consume alcohol regularly as this could affect your treatment with this medicine.
Pregnancy and breast-feeding
The use of Mirvaso is not recommended during pregnancy. This is because its effects on your unborn
baby are unknown. You should not use this medicine during breast-feeding.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before using this medicine.

Driving and using machines
Mirvaso has no significant influence on the ability to drive and use machines.

Mirvaso contains:
- Methylparahydroxybenzoate which may cause allergic reactions (possibly delayed).
- Propylene glycol which may cause skin irritation.

3. How to use Mirvaso
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if
you are not sure.

Important: Mirvaso is intended for adults and only for use on the skin of the face. Do not use this
medicine on other parts of your body, especially moist body surfaces, e.g. your eyes, mouth, nose or
vagina.
Do not swallow.
Keep Mirvaso gel away from children.

How to use Mirvaso
Mirvaso is recommended to be applied to the face once a day only.

During the first week, start the treatment with a small amount of gel as explained by your doctor or
nurse.

If your symptoms remain the same or improve only slightly, you may then gradually increase the
amount of gel. Spread it smoothly and evenly as a very thin layer as directed by your doctor or nurse.
It is important not to exceed the maximum daily dose of 1g (5 pea sized amounts applied to the whole
face).

If your symptoms worsen during treatment with Mirvaso (increased redness, or burning), stop
treatment and make an appointment to see your doctor – see also warnings and precautions.

You must avoid the eyes, eyelids, lips, mouth, and the inside of the nose. Should any gel get onto these
areas, wash them immediately with plenty of water. If you experience worsening of redness or burning
you should stop using Mirvaso and contact your doctor if needed.

Do not apply any other skin medicines or cosmetics immediately before the daily application of
Mirvaso. You should use these products only after the applied Mirvaso has dried.
You should wash your hands immediately after applying this medicine.

Pay attention when opening the tube / pump for the first time, not to spill a larger quantity of gel than
what is needed. If this occurs, you should discard the excess gel so as not to apply more than the
recommended dose. See paragraph “How to use Mirvaso” above.

How to open the tube with a child-resistant cap
To avoid spilling, do not squeeze the tube while opening or closing.
Push down on the cap and turn counterclockwise (turn a quarter of a turn to the left). Then pull the cap
off.
How to close the tube with a child-resistant cap
Align grooves on the cap and tube. Push down and turn clockwise (turn a quarter of a turn to the right).

[EU/1/13/904/004-006]

How to open the tube with a child-resistant cap
To avoid spilling, do not squeeze the tube while opening or closing.
Push down on the cap and turn counterclockwise (turn to the left). Then pull the cap off.

How to close the tube with a child-resistant cap
Push down and turn clockwise (turn to the right).

[EU/1/13/904/007]

How to open the pump with a child-resistant cap
Push down on the cap and turn counterclockwise (turn to the left) until the cap can be removed.
Note: when the cap is removed, the pump is not child-resistant.

Before the first use, prime the pump by pressing down several times until the medicine is idispensed onto your fingertip.
To apply Mirvaso gel to your face, dispense a pea-sized amount of Mirvaso from the pump onto your fingertip.
To close the pump, place the cap back on the pump. Push down and turn the cap to the right (clockwise) until it stops. The pump is child-resistant again.

If you use more Mirvaso than you should
If you use more than the maximum daily dose within a 24 hour period, it could lead to skin irritation or other side effects at the application site. Repeated doses within the same 24 hour period could result in side effects, such as low blood pressure, drowsiness or sleepiness.

Please contact your doctor, who will advise you on what action to take.

If anyone, especially a child, accidentally swallows Mirvaso, they may have serious side effects and need to be treated in a hospital.

Contact your doctor immediately or go to a hospital emergency department right away if you, a child, or anyone else swallows this medicine and has any of these symptoms: feeling dizzy from low blood pressure, vomiting, tiredness or drowsiness, decreased or irregular heartbeats, small pupils (constricted pupils), difficult or slow breathing, floppiness, low body temperature and convulsions (fits). Take the medicine pack with you, so the doctor knows what was swallowed.

If you forget to use Mirvaso
Mirvaso works on a daily basis, starting with the first day of treatment. If you miss a daily dose, your redness will not be reduced for that day. Do not use a double dose to make up for a forgotten dose.

If you stop using Mirvaso
Please contact your doctor before stopping your treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you develop severe irritation or contact allergy (e.g. allergic reaction, rash), uncommon side effects, stop using Mirvaso and see your doctor. In some cases, symptoms may extend beyond the treatment area.

Mirvaso may also cause the following other side effects:

Common side effects (may affect up to 1 in 10 people):
- flushing
- excessive whitening (pallor) where the gel is applied
- skin redness, burning feeling of the skin or itching
Uncommon side effects (may affect up to 1 in 100 people):
- acne
- dry mouth
- feeling cold in hands and feet
- feeling hot
- headache
- nasal congestion
- skin rash, skin pain or discomfort, skin irritation or inflammation, dry skin, warm skin sensation, tingling or sensation of pins and needles
- swelling of the eyelid
- swelling of the face
- urticaria
- worsening of rosacea
- dizziness

Rare side effects (may affect up to 1 in 1000 people):
- angioedema (a serious allergic reaction usually with swelling of the face, mouth or tongue).
  Stop treatment if this occurs
- hypotension (blood pressure decreased)
- heart rate decrease (slow heart rate, known as bradycardia).

Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Mirvaso

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, tube and pump after EXP.
The expiry date refers to the last day of that month.

This medicine does not require any special storage condition.
Do not freeze.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Mirvaso contains
- The active substance is brimonidine. One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.
- The other ingredients are carbomer, methylparahydroxybenzoate (E218), phenoxyethanol, glycerol, titanium dioxide, propylene glycol, sodium hydroxide, purified water. See end of section 2 for information on methylparahydroxybenzoate and propylene glycol.

What Mirvaso looks like and contents of the pack
Mirvaso is a white to light yellow, opaque gel. It is supplied in tubes containing 2, 10 or 30 grams of gel or in airless pump system containing 30 g of gel.

Pack size of 1 tube or 1 pump.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder
Galderma International
Tour Europlasca, 20 avenue André Prothin – La Défense 4
La Défense Cedex 92927
France

Manufacturer
Laboratoires Galderma
Z.I. Montdésir
74540 Alby-sur-Chéran
France

And

Galderma Laboratorium GmbH
Georg-Glock-Str. 8
D-40474 Düsseldorf
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**Österreich**
Galderma Austria GmbH
Tel: 0043 732 715 993
e-mail: austria@galderma.com

**Italia**
Galderma Italia S.p.A.
Tel: + 39 039 63 4691

**Belgique/Belgium**
Galderma Benelux BV
Tél/Tel: +31 183691919
e-mail: info.be@galderma.com

**Latvija**
H. Abbe Pharma GmbH
Tel: +371/67/103205
e-mail: birojs.habbe@apollo.lv

**България**
Елана Фарм ООД
София, ул."Плачковица"9, ст.3
Тел.: + 359 2 962 15 26
e-mail: office@elanapharm.com

**Lietuva**
H. Abbe Pharma GmbH atstovybė
Tel: +370/52/711710
e-mail: info@abbepharma.lt

**Česká republika**
Galderma-Spirig Česká a Slovenská republika a.s.
Tel: +421 2 49 10 90 10
e-mail: czsk@galderma.com

**Magyarország**
Ewopharma Hungary Kft.
Tel.: +36 1 200 4650
e-mail: info@ewopharma.hu

**Danmark**
Galderma Nordic AB
Tel/Sim/Puh/Tel: + 46 18 444 0330
e-mail: nordic@galderma.com

**Malta**
Prohealth Limited
Tel. +356 21461851, +356 21460164
e-mail:info@prohealth.com.mt
This leaflet was last revised in XX/XXX.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
ANNEX IV

SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S)
Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for brimonidine (centrally authorised product only), the scientific conclusions of CHMP are as follows:

Bradycardia as a systemic alpha-2 adrenergic effect of Mirvaso is highly plausible, if absorbed systemically in sufficient amount. Cumulatively, 6 cases of bradycardia-related terms were reported, and although confounding factors exist in some cases, overall the evidence is considered to be suggestive of an association between Mirvaso and bradycardia, particularly when applied to inflamed skin. This is also supported by the previously identified adverse event of hypotension, as alpha-2 adrenergic stimulation would be expected to cause both effects. Therefore, the PRAC considered that section 4.8 of the SmPC should be updated to add the adverse reaction ‘bradycardia’ with a frequency ‘rare’.

Dizziness is a common symptom of the already listed adverse event ‘hypotension’. Cumulatively 37 post-marketing reports of the preferred term dizziness have been received and of the cumulative total of 18 cases discussed in this PSUR under ‘haemodynamic effect’ as suggestive of an alpha-2 adrenergic effect of brimonidine, 9 cases included an event of dizziness. The PRAC considers that the evidence is suggestive of a causal association between brimonidine gel and dizziness, therefore the PRAC concluded that section 4.8 of the SmPC should be updated to add the adverse reaction ‘dizziness’ with a frequency ‘uncommon’.

Of the 18 cases discussed by the MAH as suggestive of an alpha-2 adrenergic effect of brimonidine, 6 occurred after Mirvaso was applied following recent laser therapy, and 1 case of bradycardia was associated with application to sun-burned skin. It is biologically plausible that increased systemic absorption via inflamed skin could increase the risk of systemic haemodynamic effects; therefore although a relationship cannot be definitely proven, the available evidence supports an association between recent laser therapy and the occurrence of haemodynamic adverse events on application of Mirvaso. Therefore, the PRAC considered that section 4.4 of the SmPC should be updated to add a warning on the risk of haemodynamic effects following laser therapy.

Therefore, in view of the data presented in the reviewed PSUR, the PRAC considered that changes to the product information of medicinal products containing brimonidine were warranted.

The CHMP agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for brimonidine (centrally authorised product only) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing brimonidine (centrally authorised product only) is unchanged subject to the proposed changes to the product information.

The CHMP recommends that the terms of the marketing authorisation(s) should be varied.